The deal marks the latest in a series of distribution agreements MDxHealth has recently signed for the SelectMDx test.
Abacus ALS will handle sales and technical support for Gyros Protein Technologies' immunoassay products in Australia and New Zealand.
The Teva Pharmaceuticals subsidiary will have exclusive rights to distribute NantHealth's comprehensive molecular cancer test in Israel.
The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
The firm offered a qualitative assessment of third quarter business activities, and announced a private placement and a US distribution deal with Thermo Fisher.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.
Rosetta's test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.